Drug
Imiquimod clinical trials
Also written Aldara and Zyclara.
- studies test it
- 126
- open now
- 7
- in phase 3
- 36
- first study started
- 1999
Keep track of what changes. Save the Imiquimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
123 studies that test it; most in 2008 (19)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 19 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 6
- Phase 1
- 23
- Phase 2
- 35
- Phase 3
- 36
- Phase 4
- 23
- No phase
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 93
Graceway Pharmaceuticals, LLC (10) · MEDA Pharma GmbH & Co. KG (8) · The University of Hong Kong (4) · Maastricht University Medical Center (4) · University Hospital Tuebingen (3) · Medical University of Graz (3) · Medical University of Vienna (3) · University of Michigan (2)
Often tested with
Tested in the same studies.
Fluorouracil (5) · Cyclophosphamide (2) · Pembrolizumab (1) · Candida albicans Antigen Injection (1) · Histamine phosphate (1) · Histamine (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1) · Human Papillomavirus Tumor Antigen Vaccine (1)
Studies
Open first, then newest update. How each study uses Imiquimod is read from its arms, and is right about nine times in ten.
Testing it · 126
- Basal Cell Carcinoma Chemoprevention TrialRecruitingPhase 3VA Office of Research and DevelopmentNCT05212246Written as 5% Imiquimod cream
- Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma PatientsNot yet recruitingPhase 1/2Centre Leon BerardNCT07679841Written as Imiquimod 5% cream
- Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis FungoidesRecruitingEarly Phase 1Northwestern UniversityNCT05838599Written as Imiquimod
- Topical Imiquimod Treatment of Oral DysplasiaRecruitingPhase 1/2University of Southern CaliforniaNCT07210775Written as Imiquimod (topical use)
- Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with ImiquimodRecruitingPhase 4Barretos Cancer HospitalNCT06356012Written as Imiquimod
- Deep Phenotyping of Cutaneous Lupus ErythematosusRecruitingNot applicableCentre for Human Drug Research, NetherlandsNCT06411106Written as IMIQUIMOD cream 50mg/g
- CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsRecruitingPhase 1OX2 TherapeuticsNCT06305910Written as Treatment with CD200AR-L
- Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the FaceCompletedPhase 3Nantes University HospitalNCT01720407Written as Imiquimod cream + surgery
- Investigating the Effect of Topical Imiquimod on Sebaceous HyperplasiaCompletedPhase 4University of MichiganNCT06840470Written as Imiquimod 5% Topical Cream
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and ImiquimodTerminatedPhase 2Beth Israel Deaconess Medical CenterNCT00799110Written as imiquimod
- Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaCompletedEarly Phase 1Mayo ClinicNCT03276832Written as Imiquimod
- Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With ImiquimodTerminatedPhase 1James FelkerNCT01795313Written as Imiquimod
- A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell CarcinomaCompletedPhase 2Melanoma Institute AustraliaNCT03534947Written as Imiquimod
- Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin LesionsCompletedPhase 3AIDS Malignancy ConsortiumNCT02059499Written as imiquimod
- Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial NeoplasiaCompletedEarly Phase 1National Cancer Institute (NCI)NCT03196180Written as Imiquimod
- Immunologic Profile of Chronically Photodamaged SkinCompletedPhase 1University of MichiganNCT02889159Written as imiquimod 5% cream
- Neoadjuvant Imiquimod Immunotherapy for Oral CancerCompletedEarly Phase 1Medical University of South CarolinaNCT04883645Written as Imiquimod 5% Cream
- Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsCompletedPhase 3AIDS Malignancy ConsortiumNCT02135419Written as imiquimod
- Radiotherapy or Imiquimod in Complex Lentigo MalignaCompletedPhase 3Melanoma and Skin Cancer Trials LimitedNCT02394132Written as Imiquimod
- Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)CompletedPhase 2Yale UniversityNCT02864147Written as Imiquimod
See all 126 studies that test Imiquimod →
Given in every arm · 16 — Imiquimod is usual care beside what is tested
- IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade AstrocytomasNot yet recruitingPhase 2German Cancer Research CenterNCT07888647Written as Imiquimod 5 % Cream
- Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell CarcinomaRecruitingPhase 1/2Instituto Oncológico Dr RosellNCT07251413Written as Topical imiquimod
- Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02600949Written as Imiquimod
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedPhase 1Toray Industries, IncNCT03872947Written as Imiquimod Cream
- Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedPhase 1/2Stemline Therapeutics, Inc.NCT02078648Written as Imiquimod
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of ItchWithdrawnNot applicableAalborg UniversityNCT03943407Written as Zyclara 3.75 % Topical Cream
- Dendritic Cell Vaccine for Children and Adults With SarcomaCompletedPhase 1Macarena De La Fuente, MDNCT01803152Written as Imiquimod
- Coadministration of GA2 Sporozoites With AdjuvantsStatus unknownEarly Phase 1Leiden University Medical CenterNCT05468606Written as Imiquimod
- Dendritic Cell (DC) Vaccine for Malignant Glioma and GlioblastomaCompletedPhase 1Macarena De La Fuente, MDNCT01808820Written as Imiquimod
- Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast CancerTerminatedPhase 1Washington University School of MedicineNCT03982004Written as Topical imiquimod
- A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownPhase 1Xiangya Hospital of Central South UniversityNCT04072900Written as Imiquimod 5% Topical Cream
- H5N1 With or Without Topical Aldara in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03472976Written as Imiquimod
- Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain TumorCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT01171469Written as Imiquimod
- Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of MelanomaCompletedPhase 1University of VirginiaNCT01264731Written as Imiquimod
- Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSILTerminatedPhase 1GenticelNCT02689726Written as Aldara
- Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic TherapyTerminatedPhase 4Tennessee Clinical Research CenterNCT01203878Written as Imiquimod
As the comparator · 10 — what is tested is compared with Imiquimod
- Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%CompletedPhase 4LEO PharmaNCT01926496Written as Imiquimod Cream, 5%
- Gene and Protein Expression Profiles After Treatment of Actinic KeratosesStatus unknownPhase 2Ismail GögenurNCT05740969Written as Imiquimod
- Efficacy of Tazarotene in Treatment of Verruca PlanaStatus unknownPhase 2Zagazig UniversityNCT05314127Written as Imiquimod
- Efficacy and Tolerability of Topical LFX453 for External Genital WartsCompletedPhase 2Novartis PharmaceuticalsNCT02482428Written as Aldara
- Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic KeratosisCompletedPhase 3Teva Pharmaceuticals USANCT01686152Written as Zyclara®
- Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled StudyStatus unknownPhase 3Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo FabbriNCT03901690Written as Imiquimod 5% cream
- Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant RecipientsTerminatedPhase 4Medical University of ViennaNCT01538901Written as imiquimod 5% cream
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453CompletedPhase 1Novartis PharmaceuticalsNCT02052687Written as Imiquimod
- Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.CompletedPhase 1Taro Pharmaceuticals USANCT01788007Written as Zyclara® (imiquimod) Topical Cream 3.75%
- Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo MalignaCompletedNot applicableUniversity of UtahNCT00707174Written as Imiquimod Cream
Codes
What other systems call Imiquimod · ClinicalTrials.gg INT006684
- MeSH (NLM) D000077271ImiquimodConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P1QW714R7MIMIQUIMODConfirmed FDA, NLM, Wikidata
- RxNorm 59943Confirmed FDA, Wikidata
- Wikidata Q423417imiquimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1431ImiquimodOne source FDA
- DrugBank DB00724One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077271 | Imiquimod | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P1QW714R7M | IMIQUIMOD | Confirmed FDA, NLM, Wikidata |
| RxNorm | 59943 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423417 | imiquimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1431 | Imiquimod | One source FDA |
| DrugBank | DB00724 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.